Collagen News and Research RSS Feed - Collagen News and Research

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Platform therapeutic company Symic Biomedical, Inc. announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis. [More]
IUPUI researcher receives NIH grant to study role of collagen in bone fracture resistance

IUPUI researcher receives NIH grant to study role of collagen in bone fracture resistance

A biomedical engineer researcher at Indiana University-Purdue University Indianapolis has received a $419,000 National Institutes of Health grant to uncover why mechanical loading of bones increases their resistance to fractures. [More]
MiMedx Group reports record revenues and earnings for Q2 2015

MiMedx Group reports record revenues and earnings for Q2 2015

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the second quarter of 2015. [More]
Researchers demonstrate direct connection between NOX proteins and liver fibrosis

Researchers demonstrate direct connection between NOX proteins and liver fibrosis

Researchers at the University of California, San Diego School of Medicine have demonstrated a direct connection between two signaling proteins and liver fibrosis, a scarring process underlying chronic liver disease, the 12th leading cause of death in the United States. [More]
Researchers develop dynamic functional mouse model for lung injury repair

Researchers develop dynamic functional mouse model for lung injury repair

Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested. [More]
Recipients of GSA poster awards announced at 20th International C. elegans Meeting

Recipients of GSA poster awards announced at 20th International C. elegans Meeting

The Genetics Society of America and the C. elegans research community are pleased to announce the recipients of the GSA poster awards at the 20th International C. elegans Meeting, which took place at the University of California, Los Angeles, June 24-28, 2015. [More]
RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 phase 1 human clinical trial. [More]

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that Asahi Kasei Pharma Corporation has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for XIAFLEX (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren's contracture in Japan. [More]

Researchers develop new approach for better integrating medical devices with biological systems

Researchers have developed a new approach for better integrating medical devices with biological systems. The researchers, led by Bozhi Tian, assistant professor in chemistry at the University of Chicago, have developed the first skeleton-like silicon spicules ever prepared via chemical processes. [More]
Botanic Choice releases list of top 10 supplements for 2015

Botanic Choice releases list of top 10 supplements for 2015

Botanic Choice has just released its list of the top 10 most popular supplements for the first half of 2015. [More]
Dental pulp stem cell transplants can contribute to peripheral nerve regeneration

Dental pulp stem cell transplants can contribute to peripheral nerve regeneration

Peripheral nerve injuries often are caused by trauma or surgical complications and can result in considerable disabilities. Regeneration of peripheral nerves can be accomplished effectively using autologous (self-donated) nerve grafts, but that procedure may sacrifice a functional nerve and cause loss of sensation in another part of the patient's body. [More]
Special issue provides comprehensive overview of latest findings in the area of skeletal research

Special issue provides comprehensive overview of latest findings in the area of skeletal research

While there is good understanding of how bone mass, and more recently bone architecture, affects fracture risk, far less is known about the material properties of bone, or how these can impart resilience or fragility to the skeleton. [More]
First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections. [More]
Newcastle University scientists document action spectrum of ultraviolet damage in skin cells

Newcastle University scientists document action spectrum of ultraviolet damage in skin cells

Scientists at Newcastle University have documented for the first time the DNA damage which can occur to skin across the full range of ultraviolet radiation from the sun providing an invaluable tool for sun-protection and the manufacturers of sunscreen. [More]
NIBIB-funded researcher develops new technique for tissue analysis

NIBIB-funded researcher develops new technique for tissue analysis

An NIBIB-funded researcher has developed a new technique that creates digital pictures of a tissue's chemical composition using light and a computer. The technique replaces the need for dyes or stains, which can be costly and require significant time and effort to apply. [More]
MGH researchers develop new approach to skin rejuvenation

MGH researchers develop new approach to skin rejuvenation

A new approach to skin rejuvenation developed at Massachusetts General Hospital (MGH) may be less likely to have unintended side effects such as scarring and altered pigmentation. [More]
Implantable antibiotic-laden sponges help prevent sternal wound infections during cardiac surgery

Implantable antibiotic-laden sponges help prevent sternal wound infections during cardiac surgery

Cardiac surgeons often "crack open" the flat bone that forms the middle front section of the chest, known as the sternum, in order to reach important structures. When a sternal wound infection (SWI) occurs, serious complications and even death may result. Implanting antibiotic-laden sponges between the sternal halves before closure has been adapted to prevent infections. [More]
Nature's Bounty introduces Women's Multivitamin Gummies

Nature's Bounty introduces Women's Multivitamin Gummies

Nature's Bounty, one of the most trusted names in vitamins, supplements and nutrition, is excited to introduce its Women's Multivitamin Gummies, the newest addition to the Optimal Solutions health, beauty and wellness line. This supplement helps provide women with the nutrients needed to support a healthy, strong and beautiful body. [More]
New therapeutic target discovered for idiopathic pulmonary fibrosis

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected. [More]
Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"). [More]
Advertisement
Advertisement